RecruitingNot Applicable

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

France8,000 participantsStarted 2023-02-21

Plain-language summary

The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence, * AND adult (equal to or \> 18 years old), * AND affiliated with a social security scheme in France, * AND whose monitoring will be carried out at the recruiting center. Exclusion Criteria: * Patient being monitored for a non-urothelial bladder tumor * Patient refusing follow-up * Opposition to participation in the study * Adult protected by law

What they're measuring

Recurrence-Free Survival

Timeframe: 5 years

Performance of urine tests (biomarkers)

Timeframe: 5 years

Trial details

NCT IDNCT05002556

SponsorAssociation Francaise d'Urologie

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2034-02

Contact for this trial

Yann Neuzillet

+33145480609 registres@afu.fr

View on ClinicalTrials.gov More Non-Muscle-Invasive Bladder Cancer trials